IP Law Daily, PATENT—Fed. Cir.: Anti-filing injunction affirmed against serial litigant in patent lawsuit against IBM and other tech giants, (May 13, 2024)

By Saurabh Kashyap, B.A., LL.B., LL.M.

District court correctly dismissed the lawsuit and did not abuse its discretion in imposing anti-filing injunction against litigant with history of filing meritless suits.

The U.S. Court of Appeals for the Federal Circuit affirmed a lower court’s dismissal of a patent infringement lawsuit and imposition of an anti-filing injunction against an individual plaintiff with a history of filing frivolous and meritless patent infringement suits. The appellate court concluded that the injunction was warranted due to the individual’s history of filing numerous meritless lawsuits, particularly against high-profile corporate entities and various individuals within the judicial system (Arunachalam v. International Business Machines Corp. , No. 22-2121 (Fed. Cir. May 10, 2024)).

Background. The plaintiff/appellant, Dr. Lakshmi Arunachalam, has been a serial litigant in the federal courts, involving herself in over one hundred patent lawsuits over the years. Her complaints have frequently named major corporations, judges, lawyers, and court staff with accusations ranging from patent infringement to constitutional violations.

In the underlying patent infringement litigation that led to the instant appeal, Dr. Arunachalam claimed to be the inventor of significant technologies used in the Internet of Things, specifically "Web Apps displayed on a Web browser," and asserted that she was awarded numerous patents dating back to 1995. She sought compensatory damages of no less than $100 billion, alleging that defendants such as IBM, JPMorgan Chase & Co., Apple Inc., and Facebook Inc., among others, along with their customers and partners, used her patented technologies without compensation, enriching themselves unjustly by trillions of dollars. The district court dismissed the lawsuit and imposed an anti-filing injunction on Dr. Arunachalam. The plaintiff appealed.

Jurisdiction. The appellate court found that it had jurisdiction under 28 U.S.C. § 1295(a)(1) as the case involved a claim arising under the federal patent laws. It noted that Dr. Arunachalam’s patent claims and her allegations of infringement were sufficient to bring the case within the ambit of its appellate jurisdiction.

Injunction merits. In its analysis, the appellate court noted that Dr. Arunachalam was given clear and formal notice regarding the specific nature of the proposed injunction and the reasons behind it. It was further observed that Dr. Arunachalam had the opportunity to be heard, which she utilized by submitting a detailed 37-page opposition brief. Citing Allen v. United States, 88 F.4th 983, 986–87 (Fed. Cir. 2023), the appellate court highlighted the inherent powers of federal courts to issue injunctions against abusive litigation practices, including the repetitive filing of meritless and vexatious lawsuits. Referencing Brow v. Farrelly, 994 F.2d 1027, 1038 (3d Cir. 1993), the appellate court also pointed out that federal district courts possess the power, under the All Writs Act, to issue injunctions to prevent abuse of the judicial process.

Furthermore, the appellate court reviewed the substantive rationale provided by the district court in issuing the injunction. The district court had cited Dr. Arunachalam's extensive history of filing litigious actions that lacked merit and were considered vexatious. This history included the current extensive and unsupported allegations against numerous defendants and previous instances where similar conduct had been sanctioned. The district court referenced past sanctions and attorney fees imposed on Dr. Arunachalam due to similar behaviors, reinforcing the pattern of abuse and the necessity for judicial intervention through the injunction. Thus, the appellate court found no abuse of discretion in the lower court’s actions.

Behavioral assessment. The appellate court highlighted that the district court had correctly identified Dr. Arunachalam's litigious actions as vexatious and abusive. It pointed out that this pattern of behavior justified the extraordinary measure of an anti-filing injunction to prevent further misuse of the court system. The court also dismissed Dr. Arunachalam's argument regarding the actual number of her past lawsuits as irrelevant to the necessity for an injunction, given her acknowledged history of repetitive and meritless filings.

Scope of injunction: Ultimately, the appellate court concluded that the scope of the district court’s injunction was appropriately narrow, targeting only Dr. Arunachalam’s continued misuse of the legal system through baseless claims related to her patent rights.

The Case is No. 22-2121.

Judge: per curiam.

Attorneys: Lakshmi Arunachalam, pro se. Mark J. Abate (Goodwin Procter LLP) for International Business Machines Corp. Cliff C. Gardner (Skadden, Arps, Slate, Meagher & Flom LLP) for JPMorgan Chase & Co. Tharan Gregory Lanier (Jones Day) for SAP America, Inc.

Companies: International Business Machines Corporation; Fiserv, Inc.; JPMorgan Chase & Co.; SAP America, Inc.; Apple Inc.; Facebook, Inc.; Alphabet Inc.; Microsoft Corp.; Wells Fargo Bank, N.A.; Fulton Financial Corp.; Samsung Electronics America, Inc.; Eclipse Foundation, Inc.; Uber Technologies, Inc.; Citigroup, Inc.; Citicorp, Citibank, N.A.; Lyft, Inc.; Exxon Mobil Corp.; e Intuit, Inc.; Kronos Incorporated

Cases: Patent FedCirNews DelawareNews